Solventum (SOLV) investor relations material

Business overview and transformation

• Operates in MedSurg, Dental, and HIS segments, with MedSurg as the largest at 60% of revenue.

• Core strengths are material science and data science, leveraging legacy R&D and engineering teams.

• Underwent a three-phase transformation: commercial structure, strategic focus, and portfolio optimization.

• Completed major divestiture (Purification & Filtration) and acquisition (Acera Technologies) to enhance portfolio.

• Nearing completion of separation from former parent, with 90% of transition service agreements to end by year-end.

Financial performance and guidance

• Achieved a strong Q1, positioning for full-year guidance at the higher end of EPS range.

• Advanced $100M in Q2 orders to mitigate ERP cutover, expecting offset in Q3.

• Full-year sales growth guidance unchanged, with accelerated growth and margin expansion targeted.

• Tariff headwinds of $100M–$120M are built into guidance; oil price impact expected to be minimal.

• Programs in place to drive margin expansion and achieve 10% EPS CAGR over three years.

Innovation and growth drivers

• Focused on sustainable volume growth and innovation, with R&D now aligned by segment.

• Vitality index improved from 2% at spin to mid-teens, reflecting stronger new product pipeline.

• Recent launches include Peel and Place in wound therapy and new dental products, driving segment growth.

• HIS segment leveraging AI for autonomous coding, deeply embedded in U.S. hospitals and payer systems.

• No major pipeline catalysts announced, but ongoing product launches and AI integration are key growth levers.